Targeted Protein Degradation and Metabolic Inhibition as Complementary Therapeutic Strategies: TEAD PROTACs and NAT8L Inhibitors in Oncology

  • ACS Med Chem Lett. 2026 May 25;17(6):1249-1252. doi: 10.1021/acsmedchemlett.6c00255.
Anna C Renner  1 ,  Robert B Kargbo  2
Affiliations
  • 1. North Dakota State University, Fargo, North Dakota 58108-6050, United States.
  • 2. Independent Research Consultant, Middleton, Wisconsin 53562, United States.
PMID: 42305195 DOI: 10.1021/acsmedchemlett.6c00255
Abstract

Targeted protein degradation and metabolic inhibition represent complementary strategies in oncology. TEAD-directed PROTACs enable catalytic degradation of transcription factors that drive Hippo pathway dysregulation, while NAT8L inhibitors disrupt N-acetylaspartate metabolism in acute myeloid leukemia. These approaches address undruggable targets and chemoresistance and demonstrate potential synergy with existing therapies, highlighting emerging paradigms in precision Cancer treatment.

Products